Aug 01, 2018 7:30am EDT Rigel Announces Conference Call and Webcast to Report Second Quarter 2018 Financial Results
Jun 26, 2018 7:30am EDT Rigel Initiates Phase 1 Clinical Trial of R835, an IRAK1/4 Inhibitor for Autoimmune and Inflammatory Diseases
Jun 12, 2018 7:30am EDT Rigel To Present Phase 2 Results for Fostamatinib in Autoimmune Hemolytic Anemia at EHA
May 29, 2018 7:30am EDT Rigel Announces Availability of TAVALISSE™ (fostamatinib disodium hexahydrate) in the U.S.
May 01, 2018 4:01pm EDT Rigel Announces First Quarter 2018 Financial Results and Provides Company Update
Apr 30, 2018 7:30am EDT TAVALISSE™ (fostamatinib disodium hexahydrate) Phase 3 Data Published in the American Journal of Hematology Describes Pivotal Data and Overall Response Rate Versus Placebo
Apr 24, 2018 7:30am EDT Rigel Announces Conference Call and Webcast to Report First Quarter 2018 Financial Results
